TRACON Pharmaceuticals Announces Clinical Data Presentations at Upcoming Medical Meetings
SAN DIEGO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced presentations for TRC105 at the following upcoming medical meetings.
| Oral Presentation at Connective Tissue Oncology Society (CTOS) 2015 Annual Meeting | ||||||||||||||||
| Title: A Phase 1B Dose-Escalation Study of TRC105 (anti-Endoglin Antibody) in Combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma (STS) | ||||||||||||||||
| Session Title: Sarcoma of the Year: Angiosarcoma & Hemangioendothelioma | ||||||||||||||||
| Presenter: Steven Attia, D.O., Mayo Clinic-Jacksonville | ||||||||||||||||
| Location: The Grand America Hotel, Salt Lake City, UT, Grand Ballroom B&C | ||||||||||||||||
| Date/Time: Thursday, November 5, 2015, 1:30 PM – 3:00 PM, Mountain time | ||||||||||||||||
| Poster Presentations at Kidney Cancer Association (KCA) 14th International Kidney Cancer Symposium | ||||||||||||||||
| Title: A Phase 1B Dose-Escalation Study of TRC105 (anti-Endoglin Antibody) in Combination with Axitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC) | ||||||||||||||||
| Presenter: Toni Choueiri, M.D., Dana-Farber Cancer Institute | ||||||||||||||||
| Location: Miami Marriott Biscayne Bay, Miami, FL | ||||||||||||||||
| Date: Friday, November 6, 2015 – Saturday, November 7, 2015 | ||||||||||||||||
| Title: TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 versus AXitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC) | ||||||||||||||||
| Presenter: Toni Choueiri, M.D., Dana-Farber Cancer Institute | ||||||||||||||||
| Location: Miami Marriott Biscayne Bay, Miami, FL | ||||||||||||||||
| Date: Friday, November 6, 2015 – Saturday, November 7, 2015 | ||||||||||||||||
About TRC105
TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also being developed in combination with VEGF inhibitor treatments in wet AMD. For more information about the clinical trials, please visit TRACON’s website at http://www.traconpharma.com/clinical_trials.php.
About TRACON
TRACON develops targeted therapies for cancer, wet AMD and fibrotic diseases. TRACON’s pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 clogan@traconpharma.com Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
